利妥昔单抗联合化疗治疗回盲部弥漫大B细胞淋巴瘤的临床分析

目的探讨利妥昔单抗(美罗华)联合化疗治疗回盲部弥漫大B细胞淋巴瘤的疗效及毒副作用。方法 6例经病理检查证实为回盲部弥漫大B细胞淋巴瘤患者,5例采用利妥昔单抗联合CTNP方案化疗,1例采用CTNP方案化疗,每21天为1个周期,观察治疗前后的毒副作用及疗效。结果 5例利妥昔单抗联合化疗治疗的患者有4例达完全缓解,1例达部分缓解;另1例单纯化疗患者死于疾病进展。结论利妥昔单抗联合化疗治疗回盲部弥漫大B细胞淋巴瘤可取得较好疗效,对于高龄患者利妥昔单抗无需减量,但需注意调整化疗剂量,并监测不良反应。

Clinical analysis of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma located in ileocecal region

Objective To investigate the efficacy and safety of rituximab combined with chemotherapy in the treatment of diffuse large B-cell lymphoma located in ileocecal region. Methods A total of five patients with diffuse large B-cell lymphoma located in ileocecal region were treated with rituximab combined with CTNP regimen, while one with CTNP regimen. The efficacy and safety were evaluated during and after the therapy. Results Among five patients treated with rituximab combined with CTNP regimen, the complete remission occurred in four patients and partial remission developed in one patient. Another patient treated with simple CTNP regimen was died of disease progression. Conclusion These results indicate that rituximab combined with chemotherapy is an effective regimen for the patients with diffuse large B-cell lymphoma located in ileocecal region. The dose of chemotherapy should be adjusted in elderly patients with close observation of adverse reactions.